CN102395270B - 化合物、含有其的药物组合物、其使用方法及其制备方法 - Google Patents

化合物、含有其的药物组合物、其使用方法及其制备方法 Download PDF

Info

Publication number
CN102395270B
CN102395270B CN200980135092.1A CN200980135092A CN102395270B CN 102395270 B CN102395270 B CN 102395270B CN 200980135092 A CN200980135092 A CN 200980135092A CN 102395270 B CN102395270 B CN 102395270B
Authority
CN
China
Prior art keywords
compound
aryl
halogen
positions
alkylaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980135092.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102395270A (zh
Inventor
C·A·汤森
F·库哈达
S·梅哈尔基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
FASgen Inc
Original Assignee
Johns Hopkins University
FASgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, FASgen Inc filed Critical Johns Hopkins University
Publication of CN102395270A publication Critical patent/CN102395270A/zh
Application granted granted Critical
Publication of CN102395270B publication Critical patent/CN102395270B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3834—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN200980135092.1A 2008-07-07 2009-07-07 化合物、含有其的药物组合物、其使用方法及其制备方法 Expired - Fee Related CN102395270B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12957808P 2008-07-07 2008-07-07
US61/129578 2008-07-07
PCT/US2009/049744 WO2010005922A1 (en) 2008-07-07 2009-07-07 Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same

Publications (2)

Publication Number Publication Date
CN102395270A CN102395270A (zh) 2012-03-28
CN102395270B true CN102395270B (zh) 2014-11-12

Family

ID=41507395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980135092.1A Expired - Fee Related CN102395270B (zh) 2008-07-07 2009-07-07 化合物、含有其的药物组合物、其使用方法及其制备方法

Country Status (7)

Country Link
US (1) US20120083471A1 (https=)
EP (1) EP2303013A1 (https=)
JP (1) JP2011527345A (https=)
CN (1) CN102395270B (https=)
CA (1) CA2729767A1 (https=)
MX (1) MX2011000051A (https=)
WO (1) WO2010005922A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
CA2822039C (en) * 2010-12-16 2019-05-28 Allergan, Inc. Sulfur derivatives as chemokine receptor modulators
WO2012124744A1 (ja) * 2011-03-14 2012-09-20 大正製薬株式会社 含窒素縮合複素環化合物
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013155528A2 (en) * 2012-04-13 2013-10-17 Fasgen, Inc. Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
SG11201604611SA (en) 2013-12-18 2016-07-28 Glaxosmithkline Ip Dev Ltd Nrf2 regulators
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
US9884841B2 (en) * 2015-04-20 2018-02-06 The Regents Of The University Of Michigan Small molecule inhibitors of Mcl-1 and uses thereof
WO2016203401A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
LT3307739T (lt) 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 reguliatoriai
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
WO2019165232A1 (en) * 2018-02-23 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of phospholipid synthesis and methods of use
WO2021035031A1 (en) * 2019-08-21 2021-02-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of phospholipid synthesis and methods of use
TWI860849B (zh) 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
WO2025140544A1 (zh) * 2023-12-28 2025-07-03 南京瑞初医药有限公司 Gsdmd抑制剂及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595780A (en) * 1984-01-06 1986-06-17 Shionogi & Co., Ltd. Sulfonamido-benzamide derivatives
CN1053793A (zh) * 1990-02-02 1991-08-14 赫彻斯特股份公司 应用苄基膦酸衍生物治疗由病毒引起的疾病
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2531367A (en) * 1947-07-15 1950-11-21 Sharp & Dohme Inc N-(substituted sulfonyl)-aminobenzoic acids
DE2611705A1 (de) * 1976-03-18 1977-09-22 Josef Dipl Chem Dr Rer N Klosa N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel
DE3000377A1 (de) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
FR2509305B1 (fr) * 1981-07-08 1986-04-18 Sanofi Sa Benzamides, procede pour leur preparation et compositions pharmaceutiques les renfermant
DE69023336T2 (de) * 1990-08-22 1996-05-30 Agfa Gevaert Nv Partikeltonermaterial.
JP3577336B2 (ja) * 1994-04-26 2004-10-13 三井化学株式会社 感熱記録材料
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
JP2000006528A (ja) * 1998-06-25 2000-01-11 Fuji Photo Film Co Ltd 感熱記録材料
US6048680A (en) * 1998-12-09 2000-04-11 Eastman Kodak Company Photographic element containing pyrazoloazole coupler and a specific anti-fading combination
JP2000302793A (ja) * 1999-02-18 2000-10-31 Ono Pharmaceut Co Ltd ホスホン酸誘導体
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
EP1443919A4 (en) * 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
PL372290A1 (en) * 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
AU2003258491A1 (en) * 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
AU2004210162A1 (en) * 2003-01-29 2004-08-19 Panacos Pharmaceuticals, Inc. Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
DE602006003661D1 (de) * 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
MX2009000395A (es) * 2006-07-14 2009-01-29 Chemocentryx Inc Triazolil fenil bencenosulfonamidas.
WO2008020026A1 (en) * 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for treating dermatitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595780A (en) * 1984-01-06 1986-06-17 Shionogi & Co., Ltd. Sulfonamido-benzamide derivatives
CN1053793A (zh) * 1990-02-02 1991-08-14 赫彻斯特股份公司 应用苄基膦酸衍生物治疗由病毒引起的疾病
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COX-1/COX-2 inhibitors based on the methanone moiety;Gerd Dannhardt et al;《European Journal of Medicinal Chemistry》;20021231(第37期);147-161 *

Also Published As

Publication number Publication date
MX2011000051A (es) 2011-07-28
WO2010005922A1 (en) 2010-01-14
JP2011527345A (ja) 2011-10-27
CN102395270A (zh) 2012-03-28
CA2729767A1 (en) 2010-01-14
EP2303013A1 (en) 2011-04-06
US20120083471A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
CN102395270B (zh) 化合物、含有其的药物组合物、其使用方法及其制备方法
JP4503232B2 (ja) マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた疾患の治療法
JP5707131B2 (ja) 抗炎症性化合物とその用途
BRPI0707957A2 (pt) composto, e, método para prevenção ou tratamento de uma condição ou sintoma patológico em um mamìfero
KR20080086546A (ko) 신경병증성 통증의 치료 방법
AU2002338329A1 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
EP1408945A2 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
EP3497085B1 (en) Sulfonamides as gpr40- and gpr120-agonists
WO1996001253A2 (en) Pla2 inhibitors and their use for inhibition of intestinal cholesterol absorption
CN103380112A (zh) 作为s1p受体调节剂的吲哚衍生物
BR112012021657B1 (pt) Composto, agente farmacêutico, agente para conferir kokumi , e, tempero
US4973576A (en) Bisphophonic acid derivatives and pharmaceutical compositions containing the same
BR112018014920A2 (en) methods of modulating autophagy, treating or reducing the likelihood of onset of an autophagy-mediated condition, treating, inhibiting, reducing, decreasing, or preventing an age-related disorder, modulating the expression or activity of at least one factor transcription, treatment, prevention, reduction, inhibition or reduction of a pathological condition attributable to a state of nutrient excess, promoting longevity by modulating autophagy, increasing the length of time a mammal can lead a lifestyle active without suffering from conditions associated with aging and extending the health of a mammal.
KR20200010387A (ko) 파르네소이드 x 수용체 및 가용성 에폭사이드 가수분해효소의 이중 조절제
JP2002520419A (ja) リン有機化合物およびその使用
EP3801491A1 (en) Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses
Wellner et al. Studies on the anorectic effect of N-acylphosphatidylethanolamine and phosphatidylethanolamine in mice
WO2014114649A1 (en) Lipase inhibitors
CN107428671A (zh) 用于合成羟基‑三甘油酯的方法及其用于预防和治疗疾病的用途
WO2019229005A1 (en) Linoleic acid derivatives, pharmaceutical composition or food composition comprising said linoleic acid derivatives, and their uses
US9340574B2 (en) Inhibitors of protein tyrosine phosphatases
ES2586106T3 (es) Tratamiento de la osteoporosis
WO2025117337A1 (en) Genistein phosphate derivatives
BR112021006907B1 (pt) Compostos aromáticos, composição farmacêutica e usos da referida composição
HK40002404A (en) Sulfonamides as gpr40- and gpr120-agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141112

Termination date: 20150707

EXPY Termination of patent right or utility model